Auro Laboratories share news and announcements
BSE: 530233Pharmaceuticals & BiotechnologySmall Cap
Last close ₹212.35down ₹2.15 (1.00%)
Share price at the BSE close on 23 Oct 2026. Previous close ₹214.50.
52-week range of traded prices to 23 Oct 2026
₹159.00Low, 12 Nov 2025₹317.00High, 18 Feb 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹132 Cr2,545th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 14 Aug 2026
- 28.3
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 2.9
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 14 Aug 2026
- 10.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 14 Aug 2026
- 8.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 1.37
- Volume, BSEVolume. Shares traded on the last trading day.
- 1,968
Auro Laboratories share news and announcements
442 announcements, routine notices left out, newest first. Page 2 of 9.
May 2025
Apr 2025
Mar 2025
Feb 2025
7 Feb · Board meeting
Meeting on 14 Feb 2025: quarterly results
Dec 2024
Nov 2024
5 Nov · Board meeting
Meeting on 11 Nov 2024: quarterly results
Aug 2024
Jul 2024
31 Jul · Board meeting
Meeting on 9 Aug 2024: quarterly results
Jun 2024
14 Jun · Results
14 Jun · Results
6 Jun · Meeting
May 2024
30 May · Business
25 May · Board meeting
17 May · Board meeting
Meeting on 25 May 2024: audited results4 May · Legal
Exchange has sought clarification from Auro Laboratories Ltd on May 3, 2024 with reference to significant movement in price, in order to ensure that investors have latest relevant information ....
Apr 2024
16 Apr · COMPLIANCE CERTIFICATE UNDER REG 40(10) OF SEBI LODR REGULATIONS, 2015
5 Apr · Compliance Certificate Under Reg 7(3) Of SEBI LODR Regulations, 2015 For The Year Ended March 31, 2024
Mar 2024
Feb 2024
6 Feb · Results
6 Feb · Board meeting